FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034642961> ?p ?o ?g. }

• W2034642961 abstract "Starting from in vitro studies suggesting synergistic antitumour activity against renal cell cancer (RCC) of recombinant interleukin-2 (rIL-2) and alpha-interferon (IFN), a phase II trial was initiated to test the clinical activity of this combination. The two cytokines were administered sequentially, with the aim of reducing the risk of additive toxicity and enhancing the immunological reaction against the tumour. The original treatment schedule consisted of rIL-2 18 x 10(6) U/m2/day by continuous intravenous infusion for 120 h days 1-5, and alpha-IFN 2b, at a flat dose of 9 x 10(6) U by subcutaneous or intramuscular injection thrice in a week, from day 8 to 28. Treatment was planned to be continued for six or more 28-day cycles, depending on clinical response. 12 patients were treated according to this schedule; as some cardiovascular toxicity was experienced in this set of patients, 11 further patients were treated with half-dose rIL-2 (i.e. 9 x 10(6) U/m2/day). 17 out of 23 enrolled patients completed at least one cycle of treatment and were evaluated for response. We observed six major responses [one complete response (CR) + five partial responses (PR)] for an objective response rate of 35% [95% confidence interval (CI) 17-59%]. 5 additional patients achieved stabilisation of disease; one of them reached CR after surgical extirpation of a lung mass. Sites of response included lung, nodes and bone. Duration of response is 12+ months for CR; 17, 16, 12+, 9 and 9 months for PRs. Median survival is 16 months. Response was not significantly different between full-dose and half-dose rIL-2. Considering stable disease (SD) as responses, there seemed to be a higher chance of response for patients with smaller tumour burden (P = 0.032). The toxicity of rIL-2 treatment, mainly cardiovascular, was substantial; 9 patients experienced severe cardiotoxicity, consisting of major arrhythmias, myocardial ischaemia, reduction of ejection fraction measured with heart radionuclide scan, and were excluded from continuing treatment. Other rIL-2-related toxicities forcing exclusion from the study were severe thrombocytopenia (1 case), and generalised exfoliative dermatitis requiring steroids (1 case). Otherwise, treatment was well tolerated; rIL-2-related toxicities promptly recovered after rIL-2 discontinuation in the majority of cases, and no treatment-related deaths were reported. The half-dose rIL-2 regimen was significantly less toxic in terms of hypotension (P = 0.014), fever (P = 0.014), oliguria (P = 0.042), serum creatinine elevation (P = 0.009) and prothrombin time elongation (P = 0.038).(ABSTRACT TRUNCATED AT 400 WORDS)" @default.
• W2034642961 created "2016-06-24" @default.
• W2034642961 creator A5008534127 @default.
• W2034642961 creator A5012381175 @default.
• W2034642961 creator A5016051936 @default.
• W2034642961 creator A5017068295 @default.
• W2034642961 creator A5021644812 @default.
• W2034642961 creator A5028351870 @default.
• W2034642961 creator A5035223901 @default.
• W2034642961 creator A5048685181 @default.
• W2034642961 creator A5054582280 @default.
• W2034642961 creator A5062656872 @default.
• W2034642961 creator A5075707087 @default.
• W2034642961 creator A5076113356 @default.
• W2034642961 creator A5086614200 @default.
• W2034642961 date "1994-01-01" @default.
• W2034642961 modified "2023-09-27" @default.
• W2034642961 title "Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous α-interferon" @default.
• W2034642961 cites W1510666005 @default.
• W2034642961 cites W1528317551 @default.
• W2034642961 cites W1914396593 @default.
• W2034642961 cites W1929485758 @default.
• W2034642961 cites W1964815265 @default.
• W2034642961 cites W1966196375 @default.
• W2034642961 cites W1982838179 @default.
• W2034642961 cites W2014938202 @default.
• W2034642961 cites W2028269517 @default.
• W2034642961 cites W2060291012 @default.
• W2034642961 cites W2082162853 @default.
• W2034642961 cites W2108117103 @default.
• W2034642961 cites W2141608710 @default.
• W2034642961 cites W2167805334 @default.
• W2034642961 cites W2259178548 @default.
• W2034642961 cites W2285002277 @default.
• W2034642961 cites W2294866259 @default.
• W2034642961 cites W2326245275 @default.
• W2034642961 cites W2398799157 @default.
• W2034642961 cites W2399766730 @default.
• W2034642961 cites W2407361719 @default.
• W2034642961 cites W2413587111 @default.
• W2034642961 cites W2417878188 @default.
• W2034642961 cites W2465056471 @default.
• W2034642961 cites W3041047318 @default.
• W2034642961 cites W2414902323 @default.
• W2034642961 cites W2460517541 @default.
• W2034642961 doi "https://doi.org/10.1016/0959-8049(94)90176-7" @default.
• W2034642961 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7999416" @default.
• W2034642961 hasPublicationYear "1994" @default.
• W2034642961 type Work @default.
• W2034642961 sameAs 2034642961 @default.
• W2034642961 citedByCount "21" @default.
• W2034642961 crossrefType "journal-article" @default.
• W2034642961 hasAuthorship W2034642961A5008534127 @default.
• W2034642961 hasAuthorship W2034642961A5012381175 @default.
• W2034642961 hasAuthorship W2034642961A5016051936 @default.
• W2034642961 hasAuthorship W2034642961A5017068295 @default.
• W2034642961 hasAuthorship W2034642961A5021644812 @default.
• W2034642961 hasAuthorship W2034642961A5028351870 @default.
• W2034642961 hasAuthorship W2034642961A5035223901 @default.
• W2034642961 hasAuthorship W2034642961A5048685181 @default.
• W2034642961 hasAuthorship W2034642961A5054582280 @default.
• W2034642961 hasAuthorship W2034642961A5062656872 @default.
• W2034642961 hasAuthorship W2034642961A5075707087 @default.
• W2034642961 hasAuthorship W2034642961A5076113356 @default.
• W2034642961 hasAuthorship W2034642961A5086614200 @default.
• W2034642961 hasConcept C126322002 @default.
• W2034642961 hasConcept C126894567 @default.
• W2034642961 hasConcept C141071460 @default.
• W2034642961 hasConcept C2776256026 @default.
• W2034642961 hasConcept C2776291583 @default.
• W2034642961 hasConcept C2776390293 @default.
• W2034642961 hasConcept C29730261 @default.
• W2034642961 hasConcept C44249647 @default.
• W2034642961 hasConcept C535046627 @default.
• W2034642961 hasConcept C71924100 @default.
• W2034642961 hasConcept C90924648 @default.
• W2034642961 hasConceptScore W2034642961C126322002 @default.
• W2034642961 hasConceptScore W2034642961C126894567 @default.
• W2034642961 hasConceptScore W2034642961C141071460 @default.
• W2034642961 hasConceptScore W2034642961C2776256026 @default.
• W2034642961 hasConceptScore W2034642961C2776291583 @default.
• W2034642961 hasConceptScore W2034642961C2776390293 @default.
• W2034642961 hasConceptScore W2034642961C29730261 @default.
• W2034642961 hasConceptScore W2034642961C44249647 @default.
• W2034642961 hasConceptScore W2034642961C535046627 @default.
• W2034642961 hasConceptScore W2034642961C71924100 @default.
• W2034642961 hasConceptScore W2034642961C90924648 @default.
• W2034642961 hasLocation W20346429611 @default.
• W2034642961 hasLocation W20346429612 @default.
• W2034642961 hasOpenAccess W2034642961 @default.
• W2034642961 hasPrimaryLocation W20346429611 @default.
• W2034642961 hasRelatedWork W2002120878 @default.
• W2034642961 hasRelatedWork W2034642961 @default.
• W2034642961 hasRelatedWork W2047967234 @default.
• W2034642961 hasRelatedWork W2118496982 @default.
• W2034642961 hasRelatedWork W2295996856 @default.
• W2034642961 hasRelatedWork W2384941620 @default.
• W2034642961 hasRelatedWork W2387651727 @default.
• W2034642961 hasRelatedWork W2409580796 @default.
• W2034642961 hasRelatedWork W2421688546 @default.

• next